ClinicalTrials.gg
CompletedNCT05364021PACIFICUpdated Nov 8, 2024

Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

A Phase 1/2 interventional study of LP352 and Placebo in Developmental and Epileptic Encephalopathy, Dravet Syndrome and Lennox Gastaut Syndrome, sponsored by Longboard Pharmaceuticals. Completed at 34 sites in 2 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Longboard Pharmaceuticals (part of H. Lundbeck A/S) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies in Epilepsies, Myoclonic with a site in United States — 11 open to participants now, 17 under way, 4 of them phase 3. Epilepsies, Myoclonic · United States.

Enrollment
19th of 43
52 · median 36
Started
2022
with 6 others
Phase 1/2
6 of 61
3 open now
Registered
44th of 61
by date
Lead sponsor
5 of 61
Longboard Pharmaceuticals

Among the 61 studies in Epilepsies, Myoclonic with a site in United States, this one is the 19th largest by enrollment of the 43 interventional ones that give a count, is one of 7 that started in 2022, is one of 6 in phase 1/2, and was the 44th registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

11 of the 61 studies in Epilepsies, Myoclonic with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Epilepsies, Myoclonic with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.

Read the detailed description

This is a randomized, double-blind, parallel-group, dose-escalation, placebo-controlled study of LP352 in adults and adolescents with developmental and epileptic encephalopathies (DEE) with an average of ≥ 4 observed/countable motor seizures per 4-week period during the 12 weeks before screening while on stable antiseizure medicine (ASM).

Subjects will be randomized 4:1 to LP352 or placebo. The study will have a baseline period of 28 days, followed by a 15 day up-titration period during which time subjects will titrate up to their highest tolerated doses, and a 60-day maintenance period. After Day 75, subjects will be tapered down over a period of up to 15 days, with a follow-up visit 30 days after last dose. Enrolled subjects will be allowed to continue treatment with up to 4 concomitant ASMs at a stable dose.

03

Conditions studied

  • Developmental and Epileptic Encephalopathy
  • Dravet Syndrome
  • Lennox Gastaut Syndrome

Keywords

  • CDKL5 deficiency disorder
  • developmental and epileptic encephalopathy
  • Dravet Syndrome
  • epilepsy
  • Lennox-Gastaut Syndrome
  • treatment resistant epilepsy
  • tuberous sclerosis complex
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or non-pregnant, non-lactating female, age 12 to 65 years
  2. Diagnosis of Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and epileptic encephalopathy
  3. Has a minimum number of seizures per 4-week period while taking 1 to 4 anti-seizure medications
  4. All medications and epilepsy interventions must be stable for 4 weeks before screening and are expected to remain stable during the study
  5. The patient/parent/caregiver is able and willing to attend study visits, complete the diary and take study drug as instructed

Key Exclusion Criteria:

  1. Current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction, stroke, pulmonary arterial hypertension or abnormal blood pressure
  2. Has glaucoma, renal impairment, liver disease or any other medical condition that would affect study participation or pose a risk to the subject
  3. Current or recent history of moderate or severe depression, anorexia nervosa, bulimia or at risk of suicidal behavior
  4. Currently taking anorectic agents, monoamine oxidase inhibitors; serotonin agonists or antagonists including fenfluramine, atomoxetine, vortioxetine, or other medications for weight loss
  5. Positive test result on the drug screen, except tetrahydrocannabinol (THC) for patients taking prescribed cannabidiol
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    LP352

    Subjects will be titrated up to highest tolerated dose of LP352 during a 15-day period, followed by a 60-day maintenance period and a 15-day taper/down titration period.

    Drug: LP352

  • Placebo comparator
    Placebo

    Placebo for LP352

    Drug: Placebo

Interventions

  • DrugLP352

    LP352 administered three times daily, orally or through G-tube

  • DrugPlacebo

    Matching placebo for LP352 administered three times daily, orally or through G-tube

    Also known as: Placebo Comparator

06

What researchers measure

Primary outcomes

  1. Treatment-emergent Adverse Events

    Incidence and severity of adverse events, including serious adverse events and adverse events leading to study discontinuation and clinically significant changes in vital signs, physical examination endpoints, clinical safety laboratory values and ECGs

    Time frame: Baseline up to Day 75

  2. Columbia-Suicide Severity Rating Scale (C-SSRS) Response

    Type of Suicidal Ideation, Intensity (1 - 5, with 5 being most severe), Suicidal Behavior

    Time frame: Baseline up to Day 75

  3. Patient Health Questionnaire-9 Total Score and Question 9 Score

    Severity Rating Scale: 0 - 27; higher scores indicate greater severity of depressive disorder

    Time frame: Baseline up to Day 75

  4. Percent Change from Baseline in Observed Countable Motor Seizure Frequency (per 28 Days) During the Treatment Period

    Time frame: Baseline up to Day 75

  5. Percent Change from Baseline in Observed Countable Motor Seizure Frequency (per 28 Days) During the Maintenance Period

    Time frame: Baseline up to Day 75

Secondary outcomes

  1. Observed Plasma Concentrations of LP352 by Time and Dose

    Time frame: Baseline up to Day 75

  2. Modeled Estimate of Average Plasma Concentration

    Time frame: Baseline up to Day 75

  3. Modeled Estimate of Observed Plasma Concentration Just Prior to Dosing

    Time frame: Baseline up to Day 75

  4. Correlation of Plasma Concentration with Incidence of Treatment-emergent Adverse Events

    Time frame: Baseline up to Day 75

  5. Correlation of Plasma Concentration with Seizure Frequency

    Time frame: Baseline up to Day 75

  6. Observed and Change from Baseline Prolactin Concentration During the Treatment Period

    Time frame: Baseline up to Day 75

07

Study locations

34 sites
  • University of Arizona - Health Sciences Center
    Tucson, Arizona 85724, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Rancho Los Amigos National Rehabilitation Center (RLANRC)
    Downey, California 90242, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • Northwest Florida Clinical Research Group
    Gulf Breeze, Florida 32561, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Advent Health Orlando
    Orlando, Florida 32803, United States
  • Research Institute of Orlando
    Orlando, Florida 32806, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Hawaii Pacific Neuroscience
    Honolulu, Hawaii 96817, United States
  • Consultants in Epilepsy and Neurology
    Boise, Idaho 83702, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Mid-Atlantic Epilepsy and Sleep Center
    Bethesda, Maryland 20817, United States
  • Spectrum Health
    Grand Rapids, Michigan 49503, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Boston Children's Health Physicians LLP
    Hawthorne, New York 10532, United States
  • New York University Langone Hospital - Long Island
    Mineola, New York 11501, United States
  • Northwell Health
    New York, New York 10075, United States
  • Northeast Regional Epilepsy Group
    Staten Island, New York 10305, United States
  • OnSite Clinical Solutions LLC
    Charlotte, North Carolina 98277, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Providence Neurological Specialties-East
    Portland, Oregon 97213, United States
  • Child Neurology Consultants of Austin
    Austin, Texas 78757, United States
  • Austin Epilepsy Care Center
    Austin, Texas 78758, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • University of Washington Valley Medical Center
    Renton, Washington 98055, United States
  • Royal Brisbane Women's Hospital
    Herston, Queensland 4029, Australia
  • Queensland Children's Hospital
    South Brisbane, Queensland 4101, Australia
  • Monash Children's Hospital, Monash Health
    Clayton, Victoria 3168, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Alfred Health
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Nov 2023, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2022
First posted
May 6, 2022
StartActual
Mar 3, 2022
Primary completionActual
Nov 16, 2023
CompletionActual
Nov 20, 2023
Results delay requested
Nov 4, 2024
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05364021
Responsible party
Sponsor
First posted
May 6, 2022
Start date
Mar 3, 2022
Primary completion
Nov 16, 2023
Completion
Nov 20, 2023
Last update
Nov 8, 2024

Study contacts

Dennis J Dlugos, MD
principal investigator · Children's Hospital of Philadelphia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bexicaserin

Start the discussion